Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;25(142):381-389.
doi: 10.1183/16000617.0084-2016.

Future perspectives in pulmonary arterial hypertension

Gérald Simonneau  1   2   3 , Marius M Hoeper  4 , Vallerie McLaughlin  5 , Lewis Rubin  6 , Nazzareno Galiè  7
Affiliations
Review

Future perspectives in pulmonary arterial hypertension

Gérald Simonneau et al. Eur Respir Rev. 2016 Dec.

Abstract

While there have been advances in the field of pulmonary arterial hypertension (PAH), disease management remains suboptimal for many patients. The development of novel treatments and strategies can provide opportunities to target other mechanisms that play a role in the complex pathobiology of PAH outside of the three main pathophysiological pathways. In this review, we highlight some of the potential PAH therapies or techniques that are being, or have been, investigated in phase II clinical trials. This review also discusses potential points for consideration in the development of novel therapies that target putative disease mediators or modifiers.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at err.ersjournals.com

References

    1. Humbert M, Lau EM, Montani D, et al. . Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation 2014; 130: 2189–2208. - PubMed
    1. Galiè N, Barbera JA, Frost AE, et al. . Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834–844. - PubMed
    1. Pulido T, Adzerikho I, Channick R, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809–818. - PubMed
    1. Sitbon O, Channick R, Chin KM, et al. . Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015; 373: 2522–2533. - PubMed
    1. Humbert M, Simonneau G, Rubin LJ. A decade of achievement in pulmonary hypertension. Eur Respir Rev 2011; 20: 215–217. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources